NovoCare Wegovy $199 Offer Ends June 30, 2026: What Happens Next?
The NovoCare Wegovy offer has been a lifeline for patients starting semaglutide treatment, but time is almost up. The introductory per-month pricing for Wegovy 0.25 mg and 0.5 mg injections expires on June 30, 2026, and the pricing automatically jumps to standard self-pay rates. If you're currently on this medication, or thinking about starting, here's exactly what changes and what doesn't.
The Wegovy Offer Expires June 30, 2026. Here's What Changes
The NovoCare Wegovy offer currently provides introductory pricing for eligible self-pay patients receiving their first fills of Wegovy 0.25 mg and 0.5 mg injections. According to official Wegovy savings information, this introductory pricing expires on June 30, 2026.
After the promotional period ends, eligible self-pay patients move to NovoCare's standard self-pay pricing structure. Published pricing may vary by dosage strength and product format. Patients should review current NovoCare pricing directly through official manufacturer resources because pricing programs and eligibility requirements may change over time.
What Is the Wegovy Price Without Insurance After the NovoCare Wegovy Offer Ends?
The NovoCare Wegovy offer and Wegovy's published list price can differ significantly. Patients who do not have insurance coverage or do not qualify for savings programs may pay substantially more than those using manufacturer-sponsored offers.
According to Novo Nordisk's published pricing information, Wegovy carries a list price that serves as a reference point for uninsured and self-pay patients. However, actual pharmacy pricing may vary depending on the dispensing pharmacy and available discounts.
Patients may generally fall into one of three pricing categories:
- Patients paying the published retail or list price without insurance or savings assistance
- Patients using manufacturer savings programs when eligible
- Self-pay patients purchasing through manufacturer direct-purchase or self-pay programs
Because pricing programs, eligibility requirements, and savings offers can change, patients should verify current costs directly through official NovoCare and Wegovy resources before making treatment decisions.
If your insurance plan covers Wegovy, manufacturer savings programs may help reduce your out-of-pocket expenses. Reviewing your coverage details and available savings options before the introductory offer ends can help you better understand your expected monthly costs.
What Does the Planned 2027 Wegovy Price Reduction Mean for Patients?
Novo Nordisk has announced a planned reduction in Wegovy's wholesale acquisition cost beginning January 1, 2027. While this future pricing change may improve affordability for some patients, it does not affect the expiration of the NovoCare Wegovy offer on June 30, 2026.
For patients currently using the introductory pricing program, the more immediate consideration is understanding what their monthly costs may look like after the promotion ends. Because insurance coverage, pharmacy pricing, and savings program eligibility vary, patients should review their options well before the June deadline and continue monitoring official Novo Nordisk and NovoCare updates for future pricing changes.
What Are Your Options After the Wegovy $199 Offer Expires?
If your monthly costs increase after the NovoCare Wegovy offer expires, several options may be available depending on your insurance coverage, eligibility, and treatment plan. You may wish to:
- Review your insurance benefits to determine whether Wegovy is covered under your prescription drug plan.
- Check whether you qualify for ongoing Wegovy savings programs through NovoCare.
- Speak with your healthcare provider about long-term affordability considerations.
- Compare pharmacy pricing and available prescription savings resources.
- Confirm expected out-of-pocket costs before the introductory pricing period ends.
Patients may compare a variety of licensed pharmacy providers as part of their medication access research. Some also review services such as Polar Bear Meds alongside insurance coverage and manufacturer savings programs.
Because pricing programs and eligibility requirements can change, patients should verify all current information directly through official NovoCare and Wegovy resources before making treatment decisions.
What Patients Should Do Before June 30, 2026
If you are currently using the NovoCare Wegovy offer, taking action before the expiration date may help you avoid unexpected cost increases. Consider the following steps:
- Review your current insurance coverage and prescription benefits.
- Confirm whether you remain eligible for any ongoing savings programs.
- Check expected pricing after the introductory offer expires.
- Discuss future medication costs with your healthcare provider.
- Evaluate available savings and medication access options before renewing your prescription.
Planning ahead can help you better understand your available options and prepare for any pricing changes that may occur after June 30, 2026.
What Happens Next After the NovoCare Wegovy $199 Offer Ends?
The NovoCare Wegovy $199 offer ends on June 30, 2026, which may increase costs for eligible self-pay patients. Your future price will depend on factors such as insurance coverage, savings program eligibility, and Canadian pharmacy pricing.
Before the deadline, review your benefits, explore available NovoCare savings options, and discuss long-term costs with your healthcare provider. Since pricing and eligibility rules can change, always check official NovoCare and Novo Nordisk resources for the latest information.
Frequently Asked Questions
According to NovoCare's published savings information, the introductory $199 pricing for eligible self-pay patients receiving initial Wegovy 0.25 mg and 0.5 mg fills expires on June 30, 2026. After that date, patients should review current NovoCare pricing and eligibility requirements because available offers, self-pay pricing, and program terms may change over time.
Depending on your circumstances, options may include manufacturer savings programs, insurance coverage reviews, patient assistance resources, charitable assistance organizations, or discussing alternative medications with your healthcare provider. Eligibility and costs vary by patient and treatment plan.
Zepbound (tirzepatide) is another FDA-approved prescription medication used for chronic weight management in eligible patients. Patients interested in comparing treatment options should discuss differences in cost, coverage, eligibility, and prescribing considerations with their healthcare provider.
Novo Nordisk has announced future pricing changes for Wegovy beginning in 2027. Patients should continue monitoring official Novo Nordisk and NovoCare communications because pricing programs and availability may change before those updates take effect.
Some manufacturer savings programs may remain available after the introductory offer expires. Eligibility depends on factors such as insurance status, prescription coverage, and program requirements. Patients should review the latest NovoCare savings information to determine which offers may still apply.
Disclaimer
This article walks through what the research says about Wegovy pricing and savings programs, but it's not medical or financial advice. Drug costs, insurance coverage, and savings program eligibility can change, and your specific situation may differ from what's described here. Talk to your prescriber and pharmacist before making any changes to your treatment plan based on cost alone.
